Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 21,033 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Hodgkin's Disease, Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions: LY2127399, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Irving, Texas

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Lung Diseases, Asthma
Interventions: Montelukast, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 3 Months to 3 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: fludarabine, treosulfan, allogeneic blood or bone marrow transplantation; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Neoplasms, Lymphoma
Interventions: Pazopanib, Pazopanib (GW786034)(GW786034); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Allergy
Interventions: Short Ragweed Pollen Allergenic Extract, Placebo; Biological
Lead sponsor: Greer Laboratories; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Warrenton, Virginia

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Testosterone enanthate, Megestrol acetate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Mantle Cell Lymphoma
Interventions: Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab, Bone Marrow Biopsy, Core Biopsy, FDG-Positron Emission Tomography and Computed Tomography Scan, Neurologic Examination, Patient Observation, Biospecimen Collection, Bone Marrow Aspiration; Drug · Biological · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2038
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cognitive Decline, Mild
Interventions: Blueberry, Walking, Placebo, Stretching; Dietary Supplement · Behavioral
Lead sponsor: Appalachian State University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
Interventions: CX-2029; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more

Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
Interventions: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV Infection
Interventions: Zidovudine (AZT) & Interleukin-2 (IL2); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Allogeneic Bone Marrow Transplant; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Lymphocytic Leukemia
Interventions: Iodine-131 Anti-B1 Antibody; Drug
Lead sponsor: Corixa Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Palo Alto, California • New Hyde Park, New York

Conditions: Asthma
Interventions: Placebo, RO4989991; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: South Miami, Florida • Normal, Illinois • Raleigh, North Carolina + 1 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Lymphoma, Non-Hodgkin's
Interventions: Rituximab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infection
Interventions: cell phone SMS text messaging; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 4
States / cities: Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 1 more

Conditions: Facial Lipoatrophy
Interventions: SCULPTRA (poly-L-lactic acid injection); Device
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Lacrimal Apparatus Disease, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
Interventions: Dehydroepiandrosterone; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Worcester, Massachusetts • Duncansville, Pennsylvania

Search by objective public record fields.

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

On Open-Label Study in Participants With Systemic Lupus Erythematosus

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Montelukast for Early Life Wheezing

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial

Cognition, Flavonoids, Exercise, Gut Microbiome

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

Reasons for Non-treatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

A Study of RO4989991 in Patients With Allergic Rhinitis

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Study of Cell Phone SMS to Improve Adherence to ART in HIV Positive Young Women

Evaluation of the Bioavailability of Pramlintide

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

DHEA Treatment for Sjogren's Syndrome

A Study of Tocilizumab in Patients With Rheumatoid Arthritis